DecisionDx-SCC is validated to predict metastatic risk for individual SCC patients with one or more risk factors. Independent validation was established in a prospectively designed, multi-center (33 centers) study with archival tissue, in 420 patients, with known 3-year outcomes.
The study population was representative of a high-risk SCC population. Multivariate analysis shows DecisionDx-SCC provides the strongest independent prognostic information in SCC patients with one or more high-risk factors. (Ibrahim et al, 2021).
Demonstrated clinical utility
clinicians have ordered DecisionDx-SCC to help inform prognosis and subsequent management decisions
of clinicians would change patient management given DecisionDx-SCC results with 2 risk factors. (Goldberg et al, 2022)
Helping to guide SCC management
DecisionDx-SCC adds valuable information independent of clinical factors or staging criteria, and provides unique, complementary information for SCC management.
The DecisionDx-SCC test can complement our clinical way of assessing risk for patients, allowing us to make better decisions in the management of their care.”
Jason Newman, MD, FACS | Chief: Hollings Cancer Network, Director: Head and Neck Cancer, Medical University of South Carolina